These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31195782)

  • 1. Cutaneous effects of antihypertensive drugs.
    Baccino D; Merlo G; Cozzani E; Rosa GM; Tini G; Burlando M; Parodi A
    G Ital Dermatol Venereol; 2020 Apr; 155(2):202-211. PubMed ID: 31195782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eczematous reactions due to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.
    Vena GA; Cassano N; Coco V; De Simone C
    Immunopharmacol Immunotoxicol; 2013 Jun; 35(3):447-50. PubMed ID: 23672527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Antihypertensive Medications on Sepsis-Related Outcomes: A Population-Based Cohort Study.
    Kim J; Kim YA; Hwangbo B; Kim MJ; Cho H; Hwangbo Y; Lee ES
    Crit Care Med; 2019 May; 47(5):e386-e393. PubMed ID: 30688717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Skin diseases caused by antihypertensive agents].
    Watabe Y
    Nihon Rinsho; 1992 May; 50 Suppl():125-30. PubMed ID: 1355122
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term effects of antihypertensive drugs on the risk of new-onset diabetes in elderly Taiwanese hypertensives.
    Liou YS; Ma T; Tien L; Chien C; Chou P; Jong GP
    Int Heart J; 2008 Mar; 49(2):205-11. PubMed ID: 18475020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse reactions in the skin from anti-hypertensive drugs.
    Thestrup-Pedersen K
    Dan Med Bull; 1987 Dec; 34 Suppl 1():3-5. PubMed ID: 2893692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation.
    Sontheimer RD; Henderson CL; Grau RH
    Arch Dermatol Res; 2009 Jan; 301(1):65-70. PubMed ID: 18797894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exanthematous drug eruption due to valsartan.
    Ozturk G; Turk BG; Senturk B; Turkmen M; Kandiloglu G
    Cutan Ocul Toxicol; 2012 Dec; 31(4):335-7. PubMed ID: 22257082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-induced lupus: an update on its dermatologic aspects.
    Marzano AV; Vezzoli P; Crosti C
    Lupus; 2009 Oct; 18(11):935-40. PubMed ID: 19762393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photoinduced skin reactions of cardiovascular drugs-a systematic review.
    Götzinger F; Reichrath J; Millenaar D; Lauder L; Meyer MR; Böhm M; Mahfoud F
    Eur Heart J Cardiovasc Pharmacother; 2022 Jun; 8(4):420-430. PubMed ID: 35278085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frictional purpuric eruption associated with angiotensin II receptor blockers.
    Foti C; Carbonara AM; Guida S; Antelmi A; Mazzocca A; Romita P; Bonamonte D; Angelini G
    Dermatol Ther; 2014; 27(2):97-100. PubMed ID: 24703266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of antihypertensive drugs on glucose metabolism and cardiovascular events].
    Landmark K; Reikvam A
    Tidsskr Nor Laegeforen; 2009 Sep; 129(17):1740-4. PubMed ID: 19756054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions.
    Steckelings UM; Artuc M; Wollschläger T; Wiehstutz S; Henz BM
    Acta Derm Venereol; 2001; 81(5):321-5. PubMed ID: 11800136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2016 Oct; 34(10):1921-32. PubMed ID: 27454050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-induced lupus erythematosus.
    Vedove CD; Del Giglio M; Schena D; Girolomoni G
    Arch Dermatol Res; 2009 Jan; 301(1):99-105. PubMed ID: 18797892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraclass differences among antihypertensive drugs.
    Feldman RD; Hussain Y; Kuyper LM; McAlister FA; Padwal RS; Tobe SW
    Annu Rev Pharmacol Toxicol; 2015; 55():333-52. PubMed ID: 25251994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The spectrum of cutaneous reactions associated with calcium antagonists: a review of the literature and the possible etiopathogenic mechanisms.
    Ioulios P; Charalampos M; Efrossini T
    Dermatol Online J; 2003 Dec; 9(5):6. PubMed ID: 14996379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.
    Bangalore S; Kumar S; Kjeldsen SE; Makani H; Grossman E; Wetterslev J; Gupta AK; Sever PS; Gluud C; Messerli FH
    Lancet Oncol; 2011 Jan; 12(1):65-82. PubMed ID: 21123111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.
    Fournier A; Oprisiu-Fournier R; Serot JM; Godefroy O; Achard JM; Faure S; Mazouz H; Temmar M; Albu A; Bordet R; Hanon O; Gueyffier F; Wang J; Black S; Sato N
    Expert Rev Neurother; 2009 Sep; 9(9):1413-31. PubMed ID: 19769454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.